Science Daily — Samir Taneja, MD., Director of Urologic Oncology is the Primary Investigator on a clinical trial in order to test Envisioneering Technologies’ new mechanical device called TargetScan, which preliminary tests indicate can improve doctors’ ability to detect cancer and could lead to more targeted treatments—reducing life-altering side effects like impotence and incontinence.
